Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic NSCLC with PD-L1 TPS < 1%.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05990127
Study type Interventional
Source Akeso
Contact Zhifang Yao, M.D.
Phone +86-0760-89873999
Email clinicaltrials@akesobio.com
Status Not yet recruiting
Phase Phase 3
Start date November 14, 2023
Completion date November 28, 2026

See also
  Status Clinical Trial Phase
Completed NCT03037086 - Asia PDL1 Study Among NSCLC Patients N/A
Recruiting NCT05662670 - A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03274479 - PBF-1129 in Patients With NSCLC Phase 1
Recruiting NCT03502850 - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03969823 - Whole Genomic Landscape of Advanced EGFR-mutant NSCLC N/A
Completed NCT04207775 - Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Completed NCT05631678 - Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole Phase 1
Not yet recruiting NCT06461156 - A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) Phase 1
Active, not recruiting NCT04143607 - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC Phase 3
Completed NCT03414814 - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation Phase 2
Completed NCT04360915 - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects Phase 1